Mesoblast Ltd operates within the Commercial physical research sector. In addition to historical fundamental analyses, the complete report available to purchase compares Mesoblast Ltd with three other companies in this sector in Australia: Clinuvel Pharmaceuticals Limited (2018 sales of 25.75 million Australian Dollars [US$18.47 million] of which 100% was Biotechnology), Xrf Scientific Ltd (24.25 million Australian Dollars [US$17.40 million] of which 42% was Precious Metals), and Neuren Pharmaceuticals Ltd (13.76 million Australian Dollars [US$9.87 million] of which 100% was Pharmaceutical product developments).

Sales Analysis. Sales increased substantially in 2018: During the year ended June of 2018, sales at Mesoblast Ltd were A$22.42 million (US$16.08 million). This is an increase of 600.9% versus 2017, when the company's sales were A$3.20 million. Despite this increase, sales are still well below the level achieved in 2016, when Mesoblast Ltd reported sales of A$58.52 million.